Fardel O, Payen L, Courtois A, Vernhet L, Lecureur V
Detoxication et Reparation Tissulaire, Faculté de Pharmacie, INSERM U456, 2 Avenue du Pr. L. Bernard, 35043 Rennes, Cedex, France.
Toxicology. 2001 Oct 5;167(1):37-46. doi: 10.1016/s0300-483x(01)00456-5.
Biliary elimination of endogenous compounds and xenobiotics usually requires carrier-mediated systems allowing movement across the canalicular membrane of hepatocytes. The major systems implicated belong to the ATP binding cassette transporter family: P-glycoprotein (P-gp) and multidrug resistance-associated protein 2 (MRP2), principally mediate the passage into the bile of cationic and anionic compounds, respectively, whereas the bile salt export pump (BSEP) handles biliary acids and also some anticancer drugs. Expression of these canalicular proteins can be altered in response to various hormones and structurally unrelated xenobiotics. Indeed, glucocorticoids up-regulate expression of both MRP2 and BSEP in rat hepatocytes, whereas insulin induces P-gp. P-gp expression is also up-regulated by numerous chemical carcinogens, such as polycyclic aromatic hydrocarbons and 2-acetylaminofluorene and by some anticancer drugs, such as anthracyclins. 2-Acetylaminofluorene also induces MRP2; in addition, expression of this transporter in liver cells is increased in response to various drugs, such as the barbiturate phenobarbital, the chemopreventive agent, oltipraz and the anticancer drug, cisplatin. Most of the chemical inducers acting on canalicular transporter levels are well-known to up-regulate some hepatic drug metabolizing enzymes, suggesting a coordinate regulation of liver detoxifying proteins in response to these compounds.
内源性化合物和外源性物质的胆汁排泄通常需要载体介导的系统,以允许其穿过肝细胞的胆小管膜。涉及的主要系统属于ATP结合盒转运蛋白家族:P-糖蛋白(P-gp)和多药耐药相关蛋白2(MRP2),分别主要介导阳离子和阴离子化合物进入胆汁,而胆盐输出泵(BSEP)处理胆汁酸以及一些抗癌药物。这些胆小管蛋白的表达可因各种激素和结构不相关的外源性物质而改变。实际上,糖皮质激素可上调大鼠肝细胞中MRP2和BSEP的表达,而胰岛素可诱导P-gp的表达。P-gp的表达也可被多种化学致癌物上调,如多环芳烃和2-乙酰氨基芴,以及一些抗癌药物,如蒽环类抗生素。2-乙酰氨基芴也可诱导MRP2;此外,肝细胞中该转运蛋白的表达会因各种药物而增加,如巴比妥类药物苯巴比妥、化学预防剂奥替普拉和抗癌药物顺铂。大多数作用于胆小管转运蛋白水平的化学诱导剂都已知会上调一些肝脏药物代谢酶,这表明肝脏解毒蛋白会对这些化合物做出协同调节。